<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809142</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-III-08</org_study_id>
    <nct_id>NCT04809142</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer</brief_title>
  <official_title>A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Biliary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, parallel controlled, multicentre phase III clinical trial to&#xD;
      evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as&#xD;
      second-line treatment in subjects with advanced biliary cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response（DOR）</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 6 months</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Percentage of participants whose PFS has achieved at least 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 6 months</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Percentage of participants whose OS has achieved at least 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of participants whose OS has achieved at least 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Advanced Biliary Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine tablets combined with oxaliplatin injection or gemcitabine hydrochloride injection. Each cycle is 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450 Injection</intervention_name>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride</intervention_name>
    <description>Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
    <arm_group_label>TQB2450+Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin injection</intervention_name>
    <description>Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine tablets</intervention_name>
    <description>Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine hydrochloride injection</intervention_name>
    <description>Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Histologically or cytologically confirmed biliary adenocarcinoma, including&#xD;
             intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC) and&#xD;
             gallbladder cancer (GBC).&#xD;
&#xD;
        2.18 years and older,Eastern Cooperative Oncology Group (ECOG) performance status of 0 to&#xD;
        1; Life expectancy ≥ 3 months;Weight ≥40 kg or BMI ≥18.5.&#xD;
&#xD;
        3. At least one measurable lesion (based on RECIST 1.1). 4. Previous first-line gemcitabine&#xD;
        or fluorouracil-based combination chemotherapy failed.&#xD;
&#xD;
        5.Adequate laboratory indicators. 6. No pregnant or breastfeeding women, and a negative&#xD;
        pregnancy test. 7. Understood and Signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Tumor disease and medical history:&#xD;
&#xD;
               1. Has central nervous system metastases (CNS) and/or cancerous meningitis or&#xD;
                  leptomeningeal carcinomatosis;&#xD;
&#xD;
               2. Has other malignant tumors within 5 years;&#xD;
&#xD;
               3. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary&#xD;
                  with blood vessels is unclear;&#xD;
&#xD;
               4. Severe bone damage caused by tumor bone metastasis;&#xD;
&#xD;
               5. Has uncontrolled and repeated drainage pleural effusion, pericardial effusion,&#xD;
                  and ascites;&#xD;
&#xD;
               6. Partial or complete intestinal obstruction and complete biliary obstruction that&#xD;
                  cannot be relieved; 2. Previous anti-tumor therapy:&#xD;
&#xD;
               1. Has received Anlotinib Hydrochloride Capsules, Bevacizumab Injection, and immune&#xD;
                  checkpoint inhibitors such as PD-1, PD-L1, and CTLA-4 in prior treatment;&#xD;
&#xD;
               2. Have received anti-tumor therapy within 4 weeks before the first administration;&#xD;
&#xD;
               3. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;&#xD;
                  3.Comorbidities and medical history:&#xD;
&#xD;
               1. Active hepatitis B or C;&#xD;
&#xD;
               2. Kidney abnormalities;&#xD;
&#xD;
               3. Abnormal thyroid function;&#xD;
&#xD;
               4. Cardiovascular abnormalities;&#xD;
&#xD;
               5. Gastrointestinal abnormalities;&#xD;
&#xD;
               6. History of immunodeficiency;&#xD;
&#xD;
               7. Has risk of bleeding;&#xD;
&#xD;
               8. Uncontrollable active bacterial, fungal or viral infections;&#xD;
&#xD;
               9. Lung diseases, such as interstitial pneumonia, obstructive lung disease, and&#xD;
                  history of symptomatic bronchospasm;&#xD;
&#xD;
              10. Allergies to the ingredients of the study drug;&#xD;
&#xD;
              11. Have a history of neurological or psychiatric disorders&#xD;
&#xD;
              12. According to the researcher's point of view, other severe, acute or chronic&#xD;
                  medical or mental illnesses or laboratory abnormalities that may increase the&#xD;
                  risks associated with participating in the study, or may interfere with the&#xD;
                  interpretation of the study results;&#xD;
&#xD;
              13. Have a history of pituitary or adrenal dysfunction&#xD;
&#xD;
              14. Has received major surgical treatment, open biopsy, or obvious traumatic injury&#xD;
                  within 28 days before the first administration;&#xD;
&#xD;
              15. Long-term unhealed wound or fracture;&#xD;
&#xD;
              16. Has drug abuse history that unable to abstain from or mental disorders; 4. Has&#xD;
                  participated in other clinical trials within 30 days before the study. 5. Has&#xD;
                  vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first&#xD;
                  administration.&#xD;
&#xD;
                  6. Pregnant or breastfeeding women. 7. According to the judgement of the&#xD;
                  investigators, there are other factors that may lead to the termination of the&#xD;
                  study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anhui Provincal Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yueyin Pan, Doctor</last_name>
      <email>yueyinpan1965@126.com</email>
    </contact>
    <investigator>
      <last_name>Yueyin Pan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guangyu An, Doctor</last_name>
      <email>agybjcyyy@163.com</email>
    </contact>
    <investigator>
      <last_name>Guangyu An, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aiping Zhou, Doctor</last_name>
      <phone>010-87788800</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Aiping Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lei Chen, Doctor</last_name>
      <email>chenlei@pkuoh.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Lei Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital,Captical Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dondong Lin, Doctor</last_name>
      <email>ldd1231@126.com</email>
    </contact>
    <investigator>
      <last_name>Dondong Lin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, Doctor</last_name>
      <phone>010-88196340</phone>
      <email>doctorshenlin@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiahong Dong, Doctor</last_name>
      <phone>010-56118888</phone>
      <email>dongjiahong@mail.tsinghua.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jiahong Dong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoyan Lin, Doctor</last_name>
      <email>xiaoyanlin@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoyan Lin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimin Zang, master</last_name>
      <email>booszam@sina.com</email>
    </contact>
    <investigator>
      <last_name>Aimin Zang, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinghua Gao, bachelor</last_name>
      <email>gaojinghua0317@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinghua Gao, bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengde Medical University</name>
      <address>
        <city>Chengde</city>
        <state>Hebei</state>
        <zip>067000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingshan Li, bachelor</last_name>
      <email>libing200865@126.com</email>
    </contact>
    <investigator>
      <last_name>Qingshan Li, bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanqiao Zhang, Doctor</last_name>
      <email>yanqiaozhang@126.com</email>
    </contact>
    <investigator>
      <last_name>Yanqiao Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaobing Chen, Doctor</last_name>
      <email>2290773710@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaobing Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Qiu, Doctor</last_name>
      <email>tjqiuhong@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Qiu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuang Peng, Doctor</last_name>
      <email>1518364280@qq.com</email>
    </contact>
    <investigator>
      <last_name>Chuang Peng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Peoples Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haijiao Yan, Doctor</last_name>
      <email>haijiao8237@163.com</email>
    </contact>
    <investigator>
      <last_name>Haijiao Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Li, Doctor</last_name>
      <email>jdyylw@163.com</email>
    </contact>
    <investigator>
      <last_name>Wei Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

